Ireland
--:--IST
Latest
Clinical Trials in France / NCT06910878
Recruiting Observational

Urinary Tract Infections Caused by Extended-spectrum Beta-lactamase-producing Enterobacteria

NCT06910878 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-10-24
Last updated
2025-04-04

Condition(s) studied

Urinary Tract Infections

Study summary

Urinary tract infections (UTIs) are one of the most common pathologies encountered in general practice. However, with increasing bacterial resistance to antibiotics, their treatment is becoming increasingly complex. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) pose a particular challenge due to their increased resistance to many commonly used antibiotics. The aim of this thesis is to study the management of such infections by general practitioners in Bas-Rhin and to suggest possible avenues for improvement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult (≥18 years old) * Subject with an Enterobacteriaceae urinary tract infection treated in a primary care setting for urinary tract infection between June 1, 2024 and December 31, 2024 * Subject not objecting, after being informed, to the reuse of their data for the purposes of this research. * The subject's primary care physician agreeing to participate in the study Exclusion Criteria: * Subject and/or their primary care physician having expressed their opposition to participating in the study * Subject under legal protection * Subject under guardianship or curatorship

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06910878 on ClinicalTrials.gov ↗ ← All trials in France